Bio:

Noah Greisman joined the Molecular Genetics team at the Allen Institute in 2023, where he is working to develop enhancer AAVs for driving expression in specific cell populations within the brain. Prior to returning to Seattle, he contributed to the target validation team at Fulcrum Therapeutics, focusing on validating small molecule drugs in the hematological sphere, among other areas.

Noah holds a B.S. in Biology with a minor in Business Administration from Northeastern University. During his time at school, he worked at the Broad Institute using small molecule drugs to modulate E3 ligase activity for the degradation of oncoproteins. He also worked at Moderna Therapeutics, focusing on modulating the UTRs of mRNA to drive expression in specific cell types.